With the combination of two excellent technology platforms.

ARTES acquires ANAVAX virus-like particle technology from Select Vaccines ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle technology from Select Vaccines Ltd. ANAVAX is a patent-safeguarded VLP technology that can be applied to the prevention of several infectious illnesses.With the combination of two excellent technology platforms, ANAVAX and the Hansenula expression system, ARTES has positioned itself as a unique partner for the vaccine industry dapoxetineuk.com .